These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 33862558)

  • 21. Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers.
    Lombardi AJ; Hoskins EE; Foglesong GD; Wikenheiser-Brokamp KA; Wiesmüller L; Hanenberg H; Andreassen PR; Jacobs AJ; Olson SB; Keeble WW; Hays LE; Wells SI
    Clin Cancer Res; 2015 Apr; 21(8):1962-72. PubMed ID: 25609062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
    Chiappa M; Guffanti F; Bertoni F; Colombo I; Damia G
    Drug Resist Updat; 2021 Mar; 55():100744. PubMed ID: 33551306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PARP inhibitor resistance: the underlying mechanisms and clinical implications.
    Li H; Liu ZY; Wu N; Chen YC; Cheng Q; Wang J
    Mol Cancer; 2020 Jun; 19(1):107. PubMed ID: 32563252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response.
    Wurster S; Hennes F; Parplys AC; Seelbach JI; Mansour WY; Zielinski A; Petersen C; Clauditz TS; Münscher A; Friedl AA; Borgmann K
    Oncotarget; 2016 Mar; 7(9):9732-41. PubMed ID: 26799421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.
    Ceccaldi R; O'Connor KW; Mouw KW; Li AY; Matulonis UA; D'Andrea AD; Konstantinopoulos PA
    Cancer Res; 2015 Feb; 75(4):628-34. PubMed ID: 25634215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications.
    Wanderley CWS; Correa TS; Scaranti M; Cunha FQ; Barroso-Sousa R
    Front Immunol; 2022; 13():816642. PubMed ID: 35572596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies.
    del Rivero J; Kohn EC
    Oncology (Williston Park); 2017 Apr; 31(4):265-73. PubMed ID: 28412778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints.
    Franzese O; Graziani G
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment.
    Catalano M; Francesco Iannone L; Cosso F; Generali D; Mini E; Roviello G
    Expert Opin Ther Targets; 2022 Nov; 26(11):923-936. PubMed ID: 36519314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Redundancy between nucleases required for homologous recombination promotes PARP inhibitor resistance in the eukaryotic model organism Dictyostelium.
    Kolb AL; Gunn AR; Lakin ND
    Nucleic Acids Res; 2017 Sep; 45(17):10056-10067. PubMed ID: 28973445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma.
    Shen B; Huang D; Ramsey AJ; Ig-Izevbekhai K; Zhang K; Lajud SA; O'Malley BW; Li D
    Br J Cancer; 2020 Mar; 122(5):640-647. PubMed ID: 31853007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
    Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
    Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
    [No Abstract]   [Full Text] [Related]  

  • 33. Reverse the Resistance to PARP Inhibitors.
    Kim Y; Kim A; Sharip A; Sharip A; Jiang J; Yang Q; Xie Y
    Int J Biol Sci; 2017; 13(2):198-208. PubMed ID: 28255272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
    Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
    Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system.
    Bound NT; Vandenberg CJ; Kartikasari AER; Plebanski M; Scott CL
    Front Genet; 2022; 13():886170. PubMed ID: 36159999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer.
    Heitmann J; Geeleher P; Zuo Z; Weichselbaum RR; Vokes EE; Fetscher S; Seiwert TY
    Oral Oncol; 2014 Sep; 50(9):825-31. PubMed ID: 25017803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
    Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
    [No Abstract]   [Full Text] [Related]  

  • 38. Parp Inhibitors and Radiotherapy: A New Combination for Prostate Cancer (Systematic Review).
    Rivero Belenchón I; Congregado Ruiz CB; Saez C; Osman García I; Medina López RA
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition.
    Sakogawa K; Aoki Y; Misumi K; Hamai Y; Emi M; Hihara J; Shi L; Kono K; Horikoshi Y; Sun J; Ikura T; Okada M; Tashiro S
    Cancer Sci; 2013 Dec; 104(12):1593-9. PubMed ID: 24033642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.